CVA Family Office’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.4K	Buy	92 +33	+56%	+$11.2K	﹤0.01%	700
2025 Q4	$23.5K	Sell	59 -3	-5%	-$1.33K	﹤0.01%	672
2025 Q3	$28.3K	Buy	62 +1	+2%	+$407	﹤0.01%	633
2025 Q2	$19.9K	Buy	61 +24	+65%	+$6.64K	﹤0.01%	687
2025 Q1	$9.99K	Buy	37 +12	+48%	+$3.08K	﹤0.01%	793
2024 Q4	$5.88K	Buy	25 +19	+317%	+$5K	﹤0.01%	861
2024 Q3	$1.65K	Buy	+6	New	+$1.56K	﹤0.01%	1004
2024 Q2	–	Sell	-3	Closed	-$448	–	1277
2024 Q1	$448	Buy	+3	New	+$500	﹤0.01%	1033
2023 Q3	–	Sell	-15	Closed	-$2.85K	–	255
2023 Q2	$2.85K	Hold	15	–	–	﹤0.01%	860
2023 Q1	$3K	Buy	15 +5	+50%	+$1.05K	﹤0.01%	828
2022 Q4	$2.38K	Buy	10 +5	+100%	+$1.07K	﹤0.01%	815
2022 Q3	$1K	Sell	5 -5	-50%	-$954	﹤0.01%	832
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	852
2022 Q1	$2K	Buy	+10	New	+$1.52K	﹤0.01%	860